Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012 Apr 01; 18(7):2090-8.